Roche has emerged as a frontrunner in the battle against HER2-positive breast cancer, a form of the disease marked by the overexpression of the HER2 protein. This aggressive subtype represents about 15-20% of all breast cancer cases and often leads to poorer outcomes compared to other breast cancer types. Roche’s commitment to research and development in this area has resulted in...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian